Arthur C. Santora II - Apr 24, 2023 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Role
Chief Medical Officer
Signature
/s/ Dana Yaacov-Garbeli, Attorney-in-Fact
Stock symbol
ENTX
Transactions as of
Apr 24, 2023
Transactions value $
$0
Form type
4
Date filed
4/25/2023, 05:21 PM
Previous filing
Sep 9, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTX Stock Option (right to buy) Award $0 +35K $0.00 35K Apr 24, 2023 Ordinary Shares, par value NIS 0.0000769 per share 35K $0.80 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options vest over a four-year period with 25% of the options vesting on April 24, 2024, the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.